SEC Form 4 · accession 0001209191-17-037252
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 31, 2017
Accepted (ET)
Jun 2, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 31, 2017 | S | 35,539 | $23.9426 | D | 2,351,060 | D | |
| Common StockF1,F2 | Jun 1, 2017 | S | 10,722 | $23.8926 | D | 2,340,338 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $23.51 to $24.21 on May 31, 2017 and $23.69 to $24.51 on June, 1 2017. The prices reported reflect the weighted average sale prices. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.